Board Meeting in Public Tuesday, 22 July 2025

Title of Paper	Blood Stocks Update		Agenda No.	3.4
Nature of Paper	⊠ Official	□ Official Se	nsitive	
Author(s)	Darren Bowen, Assistant Director – Supply Chain			
Lead Executive	Gerry Gogarty, Director Blood Supply and Plasma for Medicines			
Non-Executive Director Sponsor	N/A			
Presenter(s) at Meeting	Darrren Bowen			
Presented for	□ Approval □ Assurance	☑ Information□ Update		
Executive Summary (max 300 word count)				
The paper provides an update on Blood Stocks, providing information on: • Recent trends that have influenced blood stock levels and collection performance • Live interventions to support performance and stock resilience in the short to medium term. • Strategic interventions to support resilience in the longer term. • Previously Considered by N/A Recommendation The Board is asked to review the paper and consider any lines enquiry for				
	discussion.			
Risk(s) identified (Link to Board Assurance Framework Risks)				
BS-02 Shortage of Blood Components / inability to meet hospital demand BD-19 Insufficient availability of universal blood groups; BD-52 Insufficient appointment capacity to meet demand DX-01 Failure to attract or retain donors.				
Strategic Objective(s) this paper relates to: [Click on all that apply]				
\Box Collaborate with partners \Box Invest in people and culture \boxtimes Drive innovation				
☐ Modernise our operations ☐ Grow and diversify our donor base				
Appendices:				